Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rentokil
RTO
|
+$514M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$210M |
| 3 |
TFI International
TFII
|
+$145M |
| 4 |
Ambev
ABEV
|
+$142M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.38B |
| 2 |
Apple
AAPL
|
+$5.7B |
| 3 |
Amazon
AMZN
|
+$3.72B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.64B |
| 5 |
Mastercard
MA
|
+$3.47B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.73% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
RB Global
RBA
$21.7B
| $220M | 0.16% |
3,797,138
-3,841,206
| -50% | -$224M |
|
152
United Therapeutics
UTHR
$26.3B
| $213M | 0.15% |
767,426
-882,216
| -53% | -$223M |
|
153
Parker-Hannifin
PH
$124B
| $212M | 0.15% |
727,269
-733,129
| -50% | -$210M |
|
154
AstraZeneca
AZN
$263B
| $207M | 0.15% |
1,525,846
-1,870,092
| -55% | -$235M |
|
|
APLS
155
DELISTED
Apellis Pharmaceuticals
APLS
| $206M | 0.15% |
3,987,745
+3,959,473
| +14,005% | +$210M |
|
156
Alliant Energy
LNT
$19.1B
| $201M | 0.14% |
3,644,956
-3,642,740
| -50% | -$195M |
|
157
Union Pacific
UNP
$178B
| $200M | 0.14% |
968,211
-142,339
| -13% | -$29.2M |
|
158
Tyler Technologies
TYL
$13B
| $198M | 0.14% |
614,596
-676,228
| -52% | -$221M |
|
159
Canadian Natural Resources
CNQ
$93.4B
| $198M | 0.14% |
7,116,346
-7,711,206
| -52% | -$220M |
|
160
Gildan
GIL
$9.38B
| $196M | 0.14% |
7,167,979
-7,112,377
| -50% | -$207M |
|
161
Visteon
VC
$2.82B
| $194M | 0.14% |
1,485,204
-2,036,390
| -58% | -$271M |
|
162
Regal Rexnord
RRX
$14B
| $193M | 0.14% |
1,608,256
-2,070,066
| -56% | -$271M |
|
163
Amgen
AMGN
$203B
| $192M | 0.14% |
732,534
+257,862
| +54% | +$69.1M |
|
164
Icon
ICLR
$13B
| $192M | 0.14% |
986,564
-1,046,692
| -51% | -$208M |
|
165
Autodesk
ADSK
$47.7B
| $191M | 0.14% |
1,021,643
-1,198,115
| -54% | -$240M |
|
166
Hasbro
HAS
$12.8B
| $191M | 0.14% |
3,128,219
-5,598,877
| -64% | -$350M |
|
167
Uber
UBER
$139B
| $190M | 0.14% |
7,676,669
-10,984,749
| -59% | -$301M |
|
168
Sensient Technologies
SXT
$5.32B
| $190M | 0.14% |
2,600,023
-2,471,815
| -49% | -$177M |
|
169
Oracle
ORCL
$345B
| $189M | 0.13% |
2,306,858
-3,141,138
| -58% | -$239M |
|
170
Cognizant
CTSH
$22.3B
| $185M | 0.13% |
3,240,241
-1,694,647
| -34% | -$99.4M |
|
171
Rockwell Automation
ROK
$51.9B
| $185M | 0.13% |
718,041
-651,465
| -48% | -$164M |
|
|
AKRO
172
DELISTED
Akero Therapeutics
AKRO
| $183M | 0.13% |
3,340,174
-5,210,744
| -61% | -$223M |
|
173
Casey's General Stores
CASY
$31.6B
| $181M | 0.13% |
806,873
-1,032,983
| -56% | -$235M |
|
174
Pfizer
PFE
$141B
| $181M | 0.13% |
3,524,312
-3,772,426
| -52% | -$181M |
|
175
Regeneron Pharmaceuticals
REGN
$69.9B
| $178M | 0.13% |
247,022
-323,524
| -57% | -$239M |
|
Similar funds
Janus Henderson Group's Q4 2022 Portfolio in Review
As of Q4 2022, Janus Henderson Group held 2,666 positions worth $140B, down 48% from $267B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Janus Henderson Group withdrew a net $148B in Q4 2022, closing 210 positions and reducing 1,907 holdings. Its most notable exit was Terminix Global Holdings, Inc., an estimated $901M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Janus Henderson Group opened a new position in Rentokil worth $510M.
- Janus Henderson Group's largest Q4 2022 buy was Rentokil: 16,564,405 shares worth $510M.
- Janus Henderson Group added most to Apellis Pharmaceuticals in Q4 2022, an estimated $210M increase.
- Janus Henderson Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $8.38B.
- Janus Henderson Group fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $901M.
- Janus Henderson Group's ten largest holdings make up 22% of its $140B portfolio in Q4 2022.
- Janus Henderson Group opened 131 new positions and closed 210 in Q4 2022.
- Janus Henderson Group's portfolio value fell 48% quarter-over-quarter to $140B.
Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.